Novo Nordisk, Europe’s largest company by market value, faced a stock market bloodbath on Friday after disappointing results ...
Novo Nordisk’s stock dives as new weight loss drug disappoints in a late-stage trial, which gave a boost to Eli Lilly shares.
Recently published studies assert that Ozempic significantly increases the risk of developing a rare eye condition called non ...
The European Union's drug regulator said it would assess two new Danish studies that link Novo Nordisk's popular diabetes ...
Shares in Ozempic maker Novo Nordisk crashed, after an experimental anti-obesity shot fell short of expectations. The shares ...
Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently ...
Novo Nordisk ( NYSE:NVO) has secured approval from the European Medicines Agency (EMA) for a kidney disease-related label ...
Danish health authorities said on Monday they would ask the European Union's drug regulator to review the findings of two ...
With U.S. headquarters in Plainsboro, Novo Nordisk told NJBIZ, "NAION is a very rare eye disease, and it is not an adverse ...
According to its website, Novo Nordisk was founded in 1923 in Copenhagen, Denmark’s capital city. It is best known for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback